Table of Contents
Chromatography Research International
Volume 2012, Article ID 846574, 5 pages
http://dx.doi.org/10.1155/2012/846574
Research Article

A Validated RP-HPLC Method for the Estimation of Pizotifen in Pharmaceutical Dosage Form

1Department of Chemistry, Krishna University, Machilipatnam 521001, India
2Department of Chemistry, GITAM University, Visakhapatnam 530045, India
3Departmentof Chemistry, NIMS University, Rajasthan 303121, India

Received 10 August 2011; Revised 6 September 2011; Accepted 7 September 2011

Academic Editor: Sibel A. Ozkan

Copyright © 2012 M. V. Basaveswara Rao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. J. Stark, L. Valenti, and G. C. Miller, “Management of migraine in Australian general practice,” Medical Journal of Australia, vol. 187, no. 3, pp. 142–146, 2007. View at Google Scholar · View at Scopus
  2. N. Barnes and G. Millman, “Do pizotifen or propranolol reduce the frequency of migraine headache?” Archives of Disease in Childhood, vol. 89, no. 7, pp. 684–685, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. G. Pierangeli, S. Cevoli, E. Sancisi et al., “Which therapy for which patient?” Neurological Sciences, vol. 27, 2, pp. S153–S158, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. J. E. Standal, “Pizotifen as an antidepressant,” Acta Psychiatrica Scandinavica, vol. 56, no. 4, pp. 276–279, 1977. View at Google Scholar · View at Scopus
  5. C. M. Banki, “Clinical observations with pizotifene (Sandomigran) in the treatment of nonmigrainous depressed women,” Archiv fur Psychiatrie und Nervenkrankheiten, vol. 225, no. 1, pp. 67–72, 1978. View at Google Scholar · View at Scopus
  6. R. Young, N. Khorana, T. Bondareva, and R. A. Glennon, “Pizotyline effectively attenuates the stimulus effects of N-Methyl-3,4-methylenedioxyamphetamine (MDMA),” Pharmacology Biochemistry and Behavior, vol. 82, no. 2, pp. 404–410, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. D. Crowder and W. P. Maclay, “Pizotifen once daily in the prophylaxis of migraine: results of a multi-centre general practice study,” Current Medical Research and Opinion, vol. 9, no. 4, pp. 280–285, 1984. View at Google Scholar · View at Scopus
  8. A. K. Dixon, R. C. Hill, D. Roemer, and G. Scholtysik, “Pharmacological properties of 4(1-Methyl-4-piperidylidine)-9,10 dihydro-4H-benzo-[4,5]cycloheptal[1,2]-thiophene hydrogen maleate (Pizotifen),” Arzneimittelforschung, vol. 27, no. 10, pp. 1968–1979, 1977. View at Google Scholar · View at Scopus
  9. M. A. Abounassif, H. A. El-Obeid, and E. A. Gadkariem, “Stability studies on some benzocycloheptane antihistaminic agents,” Journal of Pharmaceutical and Biomedical Analysis, vol. 36, no. 5, pp. 1011–1018, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. S. M. Rahman, A. Lutfulkabir, M. D. Jahan, A. Z. Momen, and A. S. Rouf, “Validation and application of RP-HPLC liquid chromatographic method for quantification of pizotifen malate in pharmaceutical solid dosage forms,” Pakistan Journal of Pharmaceutical Sciences, vol. 23, no. 4, pp. 435–441, 2010. View at Google Scholar